Two developments underscore renewed investor and clinical momentum in T-cell receptor (TCR) therapies for solid tumors. Captain T Cell closed an equity financing round to advance its autologous TCR-T pipeline, including lead program CTC-127 targeting MAGE-A4, with plans to enter the clinic in early 2027. Separately, T-knife Therapeutics filed a clinical trial application for TK-6302, a PRAME-targeted TCR-T therapy, planning a Phase I ATLAS trial pending regulatory approval. Both announcements reflect growing interest in TCR approaches for solid tumors where traditional CAR-T therapies have struggled. The companies cited manufacturing and target-selection progress and positioned their programs to begin early clinical testing in 2026–2027.